{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2Fb22d5451-6529-4cd5-ba8c-04bebe6c6778","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Acute Myeloid Leukemia \u2014 Part 5 of Our 6-Part ASH 2024 Friday Satellite Symposia Series\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/b22d5451-6529-4cd5-ba8c-04bebe6c6778\"></iframe>","title":"Acute Myeloid Leukemia \u2014 Part 5 of Our 6-Part ASH 2024 Friday Satellite Symposia Series","description":"Dr Alexander Perl from Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Richard M Stone from Dana-Farber Cancer Institute in Boston, Massachusetts, Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, Prof Andrew H Wei from Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, and moderator Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center in New York, New York, discuss updated data from ASH 2024 influencing the current and future treatment paradigm for treatment-na\u00efve and relapsed/refractory acute myeloid leukemia. Produced by Research To Practice. \r\n\n\nCME information and select publications https://www.researchtopractice.com/ASHAML24 (here).","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/47c224e0-86ca-4bc7-ae4f-bf44a06e8cdb/cover.jpg"}